Compare Corning Incorporated (GLW) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Corning (GLW) trades at $152.81, down 9.57% despite recent positive catalysts including a $3B AT&T fiber supply agreement. The stock shows strong fundamentals with revenue growth from $13.1B to $15.6B in 2025 and net income surging to $1.6B. Technical indicators show bullish momentum with the current price below key resistance levels. Analyst consensus remains positive with 57% buy ratings and a $171.25 price target representing 12% upside potential.

GLW presents a compelling opportunity driven by AI infrastructure demand and the AT&T partnership, though elevated valuation metrics (P/E 75.23) and ongoing patent litigation create near-term headwinds. The company's strong cash flow generation and dividend payments support shareholder returns while expansion in fiber optics positions it for sustained growth in the connectivity ecosystem.

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.